GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Days Inventory

YMAB (Y-mAbs Therapeutics) Days Inventory : 231.23 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Y-mAbs Therapeutics's Average Total Inventories for the three months ended in Mar. 2025 was $7.60 Mil. Y-mAbs Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2025 was $3.00 Mil. Hence, Y-mAbs Therapeutics's Days Inventory for the three months ended in Mar. 2025 was 231.23.

The historical rank and industry rank for Y-mAbs Therapeutics's Days Inventory or its related term are showing as below:

YMAB' s Days Inventory Range Over the Past 10 Years
Min: 146.94   Med: 241.35   Max: 800.27
Current: 189.07

During the past 9 years, Y-mAbs Therapeutics's highest Days Inventory was 800.27. The lowest was 146.94. And the median was 241.35.

YMAB's Days Inventory is ranked worse than
52.49% of 642 companies
in the Biotechnology industry
Industry Median: 179.595 vs YMAB: 189.07

Y-mAbs Therapeutics's Days Inventory declined from Mar. 2024 (294.01) to Mar. 2025 (231.23).

Inventory Turnover measures how fast the company turns over its inventory within a year. Y-mAbs Therapeutics's Inventory Turnover for the three months ended in Mar. 2025 was 0.39.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Y-mAbs Therapeutics's Inventory-to-Revenue for the three months ended in Mar. 2025 was 0.36.


Y-mAbs Therapeutics Days Inventory Historical Data

The historical data trend for Y-mAbs Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Days Inventory Chart

Y-mAbs Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Inventory
Get a 7-Day Free Trial Premium Member Only - 800.27 294.58 188.11 146.94

Y-mAbs Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 294.01 256.52 366.44 97.57 231.23

Competitive Comparison of Y-mAbs Therapeutics's Days Inventory

For the Biotechnology subindustry, Y-mAbs Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Y-mAbs Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Y-mAbs Therapeutics's Days Inventory falls into.


;
;

Y-mAbs Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Y-mAbs Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as

Days Inventory (A: Dec. 2024 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (5.065 + 7.214) / 2 ) / 15.251*365
=6.1395 / 15.251*365
=146.94

Y-mAbs Therapeutics's Days Inventory for the quarter that ended in Mar. 2025 is calculated as:

Days Inventory (Q: Mar. 2025 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Dec. 2024 ) + Total Inventories (Q: Mar. 2025 )) / count ) / Cost of Goods Sold (Q: Mar. 2025 )*Days in Period
=( (7.214 + 7.995) / 2 ) / 3.001*365 / 4
=7.6045 / 3.001*365 / 4
=231.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Y-mAbs Therapeutics  (NAS:YMAB) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Y-mAbs Therapeutics's Inventory Turnover for the three months ended in Mar. 2025 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Y-mAbs Therapeutics's Inventory to Revenue for the three months ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Y-mAbs Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-mAbs Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
202 Carnegie Center, Suite 301, Princeton, NJ, USA, 08540
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Executives
Michael J Rossi director, officer: President & CEO 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Thomas Gad director, officer: President and Chairman C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Torben Lund-hansen officer: Sr. VP and Head of Tech Op C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Joris Wilms officer: Sr. VP and COO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Bo Kruse director, officer: EVP, CFO, Secy & Treas. C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Vignesh Rajah officer: SVP and CMO HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Susan Laura Smith officer: Senior Vice President, CCO 5 OVERLOOK CT, LAMBERTVILLE NJ 08530
Johan Wedell-wedellsborg director, 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Biotech Aps Wg 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus director, officer: Chief Executive Officer C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed officer: Sr. VP and CSO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman officer: Sr. VP and CCO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169